Jaguar Health, Inc.
JAGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -398.21% | -2,845.72% | -91,269.93% | -16,899.88% |
| EV / EBITDA | -0.98 | -0.97 | -0.88 | -0.30 |
| Quality | ||||
| ROIC | -66.94% | -81.66% | -102.80% | -94.25% |
| Gross Margin | 83.27% | 79.13% | 83.11% | 46.18% |
| Cash Conversion Ratio | 0.75 | 0.79 | 0.67 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.75% | 31.07% | 8.41% | -9.12% |
| Free Cash Flow Growth | 10.91% | 4.42% | 0.56% | -128.83% |
| Safety | ||||
| Net Debt / EBITDA | -0.78 | -0.93 | -0.88 | -0.29 |
| Interest Coverage | -133.47 | -5.37 | -2.70 | -4.64 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.22 | 0.29 | 0.48 |
| Cash Conversion Cycle | 995.95 | 836.93 | 295.15 | 175.98 |